Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease

Movement Disorders

Volumn 22, Issue 6, 2007, Pages 757-765

  Martinez Martin, Pablo ^a   Deuschl, Gunther ^b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Clinical trials; Health related quality of life; Outcomes research; Parkinson's disease; Surgical interventions

Indexed keywords

CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; TOLCAPONE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG EFFICACY; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; MOTOR DYSFUNCTION; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT SURVEY; SUBTHALAMIC NUCLEUS; SYSTEMATIC REVIEW;

CLINICAL TRIALS; DEEP BRAIN STIMULATION; HEALTH STATUS; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 34249309571     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21407     Document Type: Short Survey

References (93)

1. Murdaugh C. Health-related quality of life as an outcome in organizational research. Med Care 1997;35(11, Suppl.):41-48.
2. Sherbourne CD, Sturm R, Wells KB. What outcomes matter to patients? J Gen Intern Med 1999;14:357-363.
3. Bowling A. Measuring health: a review of quality of life measurement scales, 3a ed. Berkshire: Open University Press; 2005. p 1-9.
4. World Health Organization Constitution. Basic documents. Geneva, Switzerland: WHO; 1948.
5. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B, editors. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincot-Raven Publishers; 1996. p 11-23.
6. Badía Llach X, Martínez Martín P. Quality of life measurement: interest and applications. In: Martínez-Martín P, Koller WC, editors. Quality of life in Parkinson's disease. Barcelona: Masson SA; 1999. p 17-36.
7. Fitzpatrick R, Davey C, Buxton MI, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2:7-8.
8. Welsh MD. Measurement of quality of life in neurodegenerative disorders. Curr Neurol Neurosci Rep 2001;1:346-349.
9. Martínez-Martín P. An introduction to the concept of "quality of life in Parkinson's disease". J Neurol 1998;245 (Suppl. 1):2-5.
10. Shindler JS, Brown R, Welburn P, Parkes JD. Measuring the quality of life of patients with Parkinson's disease. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer; 1993. p 289-300.
11. Damiano AM, Snyder C, Strausser B, Willian MK. A review of Health-related quality-of-life concepts and measures for Parkinson's disease. Qual Life Res 1999;8:235-243.
12. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584-589.
13. Schrag A, Jahansahi M, Quinn NP. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
14. Koller WC. Drug treatment for Parkinson's disease: impact on the patient's quality of life. In: Martínez-Martín P, Koller WC, editors. Quality of life in Parkinson's disease. Barcelona: Masson SA; 1999. p 79-91.
15. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkison's disease on the quality of life. Mov Disord 2005;20:224-230.
16. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
17. Task Force of the Movement Disorder Society. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17 (Suppl. 4):1-6.
18. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989;27 (Suppl. 3):178-189.
19. Wilson RS, Goetz CG. Neurologic illness. In: Spilker B, editor. Quality of life assessment in clinical trials. New York: Raven Press; 1990. p 347-356.
20. Stebbins GT, Gilley DW, Goetz CG, et al. Quality of life in Parkinson's disease patients at two years following adrenal-medulla/caudate implant. Neurology 1991;41:398.
21. Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996;40:355-366.
22. McRae C, O'Brien C, Freed C. Quality of life among persons receiving neural implant surgery for Parkinson's disease. Mov Disord 1996;11:605-606.
23. Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998;121:659-675.
24. de Bie MA, de Haan RJ, Nijssen PCG, et al. Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. Lancet 1999;354:1665-1669.
25. Martínez-Martín P, Valldeoriola F, Molinuevo JL, Nobbe FA, Rumia J, Tolosa E. Pallidotomy and quality of life in patients with Parkinson's disease: an early study. Mov Disord 2000;15:65-70.
26. Hagell P, Crabb L, Pogarell O, et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Mov Disord 2000;15:224-229.
27. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 2000;15:230-237.
28. Straits-Tröster K, Fields JA, Wilkinson SB, Pahwa R, Lyons KE, Koller WC. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn 2000;42:399-416.
29. D'Antonio LL, Zimmerman GJ, Iacono RP. Changes in health related quality of life in patients with Parkinson's disease with and without posteroventral pallidotomy. Acta Neurochir 2000;142:759-767.
30. de Bie RM, Schuurman PR, Bosch DA, de Haan RJ, Schmand B, Speelman JD, Dutch Pallidotomy Study Group. Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients. J Neurol Neurosurg Psychiatry 2001;71: 375-382.
31. Valálik I, Sagi S, Solymosi D, Julow J. CT-guided unilateral thalamotomy with macroelectrode mapping for the treatment of Parkinson's disease. Acta Neurochir 2001;143:1019-1030.
32. Gray A, McNamara I, Aziz T, Gregory R, Bain P. Wilson J, Scott R. Quality of life outcomes following surgical treatment of Parkinson's disease. Mov Disord 2002;17:68-75.
33. Carr JAR, Honey CR, Sinden M, Phillips AG, Martzke JS. A waitlist control-group study of cognitive, mood, and quality of life outcome after posteroventral pallidotomy in Parkinson's disease. J Neurosurg 2003;99:78-88.
34. Hariz GM, Lindberg M, Hariz MI, Bergenheim AT. Gender differences in disability and health-related quality of life in patients with Parkinson's disease treated with stereotactic surgery. Acta Neurol Scand 2003;108:28-37.
35. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004;62:201-207.
36. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004;61:412-420.
37. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005;57:298-302.
38. Capus L, Melatini A, Zorzon M, et al. Chronic bilateral electrical stimulation of the subthalamic nucleus for the treatment of advanced Parkinson's disease. Neurol Sci 2001;22:57-58.
39. Lagrange E, Krack P, Moro E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002;59:1976-1978.
40. Just H, Ostergaard K. Health-related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord 2002;17:539-545.
41. Martínez-Martín P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002;17:372-377.
42. Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-766.
43. Daniele A, Albanese A, Contarino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:175-182.
44. Escamilla-Sevilla F, Minguez-Castellanos A, Katati MJ, et al. Utilidad clínica de la estìmulación cerebral profunda en la enfermedad de Parkinson avanzada. Neurologia 2004;19:719-727.
45. Gomez-Esteban JC, Lezcano E, Molano A, et al. Efectos cognitivos de la estimulacion cerebral profunda sobre el núcleo subtalámico en la enfermedad de Parkinson. Neurología 2003;18:139-145.
46. Patel NK, Plaha P, O'Sullivan K, et al. MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:1631-1637.
47. Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Improvement in quality of life in patients with advanced Parkinson's disease following bilateral deep-brain stimulation in subthalamic nucleus. Eur J Neurol 2004;11:451-454.
48. Drapier S, Raoul S, Drapier D, et al. Only physical aspects of quality of life are significantly improved by bilateral subthalamic stimulation in Parkinson's disease. J Neurol 2005;252:583-588.
49. Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. J Neurosurg 2005;103:252-255.
50. Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-449.
51. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 2006;66:1811-1816.
52. Siderowf A, Jaggi JL, Xie SX, et al. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Mov Disord 2006;21:746-753.
53. Deuschl G, Schade-Brittinger C, Krak P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Eng J Med 2006;355:896-908.
54. Gronchi-Perrin A, Viollier S, Ghika J, et al. Does subthalamic nucleus deep brain stimulation really improve quality of life in Parkinson's disease? Mov Disord 2006;21;1465-1468. DOI:10.1002/mds. 20943.
55. Vingerhoets G, Lannoo E, van der Linden C, Caemaert J, Vandewalle V, van den Abbeele D, Wolters M. Changes in quality of life following unilateral pallidal stimulation in Parkinson's disease. J Psychosom Res 1999;46:247-255.
56. Woods SP, Fields JA, Lyons KE, et al. Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a one-year follow-up. Acta Neurochir 2001;143:1273-1278.
57. Block G, Liss C, Reines S, Irr J, Nibbelink D, The CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicentric 5-year study. Eur Neurol 1997;37: 23-27.
58. Koller WC, Hutton JT. Tolosa E, Capildeo R, The Carbidopa/Levodopa Study Group. Immediate-release and control led-release carbidopa/levodopa in PD. A 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
59. Pahwa R, Lyons K, McGuire D, et al. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 1997;12:677-681.
60. Grandas F, Martínez-Martín P, Linazasoro, The STAR Multicenter Study Group. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. J Neurol 1998;245 (Suppl. 1):31-33.
61. Martinez-Martin P, Grandas F, Linazasoro G, Bravo JL, The STAR Study Group. Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. Neurologia 1999;14: 338-343.
62. Martinez-Martin P, del Ser T, Aguilar M, Peto V, The QoL Study Group. Controlled-release levodopa-carbidopa (CRLC) treatment and quality of life of Parkinson's disease patients as measured by the PDQ-39. Eur J Neurol 1998;5 (Suppl. 3):171.
63. Martinez-Martin P, Koller WC. Quality of life benefit induced by controlled-release carbidopa/levodopa formulation. In: Martinez-Martin P, Koller WC, editors. Quality of life in Parkinson's disease. Barcelona: Masson SA; 1999. p 93-105.
64. Nyholm D, Nilsson Remahl Al, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
65. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
66. Goetz CG. Highlights of the North American and European experience. Neurology 1998;50 (Suppl. 5):15-16.
67. Rajput AH, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing- off" phenomenon: a double-blind, placebo controlled, multicenter trial. Neurology 1997;49:1066-1071.
68. Welsh MD, Dorflinger E, Chernik D, Waters C. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord 2000;15:497-502.
69. Durif F, Deveaux I, Pere J-J, Delumeau J-C, Bourdeix I, The F-01 Study Group. Efficacy and tolerabilty of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45:111-118.
70. Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
71. Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:963-791.
72. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61:1563-1568
73. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004;111:1053-1063.
74. Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005;53:197-202.
75. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005;112:221-230.
76. Reichmann H, Boas J, MacMahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005;111:21-28.
77. Lyons KE, Pahwa R. Conversion from sustained release carbidopa/levodopa to carbidopa/ levodopa/ entacapone (stalevo) in Parkinson disease patients. Clin Neuropharmacol 2006;29:73-76.
78. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 2000;284:1931-1938.
79. Baas HKJ, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 2001;46 (Suppl. 1):18-23.
80. Happe S, Berger K, The FAQT Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease. J Neurol 2001;248:1062-1067.
81. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
82. Noyes K, Dick AW, Holloway RG, The Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson's disease: Effect on generic and disease-specific quality of life. Value Health 2006;9:28-38.
83. Odin P, Oehlwein C, Storch A, et al. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Acta Neurol Scand 2006;113:18-24.
84. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
85. Biglan KM, Schwid S, Eberly S, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006;21:616-623.
86. Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry 2005;76:1188-1193.
87. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl. 14):290-304.
88. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demograhic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:431-435.
89. Tröster AI, Lyons KE, Straits-Tröster KA. Determinants of health-related quality of life changes in Parkinson's disease. In: Martínez-Martín P, Koller WC, editors. Quality of life in Parkinson's disease. Barcelona: Masson SA; 1999. p 55-77.
90. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000;15:216-223.
91. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200-1207.
92. Rascol O. Defining a minimal clinically relevant difference for the Unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006;21:1059-1061.
93. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.